Oncotarget: The most preferred Source of Scientific News

In many occasions, people fail to get the latest news on various fields of science and medicine merely because they are published in expensive newsletters and weekly magazines. Note that these newsletters and magazines are offered at unreasonable prices and are held by unconventional sources. For this reason, it is hard to be updated with the emerging news as they stream if you are not part of any learning institution that has subscribed to newsletters and weekly magazines. Note that this will keep you behind on the latest findings and advancements of researchers. With the help of Oncotarget, you can get rid of this annoyance.Note that there are numerous approaches people can use to get acquitted with the recent news. However, the most viable way is subscribing to a reliable online channel that broadcasts the latest information concerning the subject of your interest. In the midst of the numerous alternatives available online, experts recommend the Oncotarget.Far from its name, Oncotarget is determined in broadcasting important information about Oncology. It is evident that Oncology is the subject that Oncotarget targets. They also target other topics such as:

  • aging process
  • the Immunology system,
  • Microbiology
  • Neuroscience,
  • Endocrinology
  • Cardiology
  • Metabolism
  • Cell Biology
  • Pharmacology

Oncotarget is a multidisciplinary journal that is exclusively free to any individual who wants to get updates on oncology information or any other area of science. The journal publishes the updates on a weekly basis, and Oncotarget is one of the trusted journals that are peer-reviewed. On top of that, the journal is equipped with vast information on the development of findings of cancer, therapies, and cure.In 2015 and 2016, Oncotarget recorded an impact fact of 5.008, and it has taken home numerous awards. This has proven that Oncotarget is indeed efficient when it comes to spreading the information about oncology. On top of that, it was listed as number one publication amongst any other publication that concentrates on oncology. This makes it the most preferred source than the majority of other paid subscription newsletters. Impact Journals is the one that is responsible for peer reviewing and publishing the Oncotarget.Note that any news that is related to oncology will pop in the news feed of Oncotarget. It is evident that the popularity of the journal is increasing and their peer reviews are assisting authors to sway their findings in the field.

About Oncotarget

Oncotarget is a leading multidisciplinary traditional journal that people can access for free. The journal publishes the news online every week, and each issue will be reproduced for a particular demand. The primary objective of Oncotarget is to make scientific findings rapidly and easily accessible. They also strive to maximize the impact of research through insightful review, allowing the striking results to be shared promptly. Oncotarget tries to eradicate the border between different specialties while linking various fields of biometric science. The journal has been in the frontline when it comes to fostering the application of basic and clinical science to fight diseases. Under the governance of skilled scientists, Oncotarget assists all researchers contribute to the advancement of science.

Dr. Mikhail Blagosklonny: Researching on Cancer Treatments and Balancing Treatment Cost

Recap: Dr. Mikhail Blagosklonny on Rapamycin’s Incredible Healing Properties

Cancer is killing more people today than any other time in human history. At an early stage, cancer can be treatable, but when it is at an advanced stage, it ‘s hard to manage it. However, researchers are not giving up, and more studies are being conducted to understand this killer disease. One of such researchers is Mikhail Blagosklonny. Mikhail is a professor of oncology and works with the Rosewell Park Cancer Institute in Buffalo, New York. He is also an Editor-in-Chief of the Oncotarget. He is involved in cancer research and therapies and believes that Rapamycin is the best drug for cancer patients and can help increase their lifespan.Rapamycin has traditionally been used to prevent organ transplant rejection and to treat a rare lung disease.

However, the drug is also considered a good cancer drug. This medication has been termed by many as a miracle drug because it can treat many conditions. The drug has also been known to treat patients suffering from a condition brought about by kidney failure and anemia. The condition is known as a hemolytic-uremic syndrome.Rapamycin also helps in the treatment of Tuberous Sclerosis Complex which is a disorder that results in brain tumors, heart tumors, and tumors in other body organs. Rapamycin can also increase longevity. However, this is still not a certain fact. Research is still ongoing, and Dr. Mikhail is spearheading this research. The treatment of Alzheimer’s disease, Systematic Lupus Erythematosus, and Muscular Dystrophy is another plus for the drug.

Recap: Mikhail Blagosklonny’s Plans for Oncology

Dr. Mikhail Blagosklonny has a passion for ensuring that people of all economic standing get the best cancer care regardless of whether they can afford it or not. His work does not only revolve around cancer but aging as well. He continues to research on the causes of cancer and the reason it is affecting people of a particular age group.As a researcher, he is respected and is broadly influential among his peers. As part of his research, Dr. Mikhail is trying to figure out how to treat cancer without the patients incurring too much cost as they do today. He knows that cancer is causing havoc in our society and he hopes he can come up with a way to destroy cancer cells in a person’s body without tampering with the normal human cells.Though his research is yet to bear fruits, he is making remarkable progress. He knows that his work will help many and he hopes that one day, someone else will take over from where he will have left off his research. The society cannot ignore the fact that cancer is becoming one of the deadliest diseases in our society today. Unfortunately, the treatment for cancer can only be afforded by the well-off. So what happens to those people who can’t afford the treatment? Dr. Mikhail Blagosklonny is hoping to solve that issue and also to create a cancer-free society.

Eric Lefkofsky: Working to Modernize Cancer Treatment

One of Chicago area’s most entreprenurial tech-sci figures, Eric Lefkofsky has donated millions of dollars into cancer research trials and studies, as he has been running the race of the medical field’s most important marathon for decades: curing cancer.

Leaving his CEO role at Groupon, Lefkofsky is busy heading new health-tech company, “Tempus,” which is attempting to build an infrastructure to modernize cancer treatment around the world. To date, he is titled as the company’s President.

Lefkofsky’s exact level of involvement with Tempus is something he avoids explaining, at least to some media venues who have tried to gain a clear understanding of why he left Groupon, as he was founder. What is it about Tempus that compelled him to invest his time and energy into a new undertaking.

LinkedIn reading states that Tempus employs 29 employees. Hunter Lane is named as Director. Anil Saldanha is Vice President of Engineering. Tempus’ primary mission [https://www.tempus.com] states it is interested in effectively aiding healthcare professionals in personalized, data-driven treatment decisions. This may make a beginning by analyzing patient genetic codes, using state-of-art “genomic sequencing,” not exactly a clear job description to the lay man. This is allegedly focused on malignant tumors, and involves a slightly new term, “algorithms”. This includes breast, lung, and pancreatic cancers, and expects to delve into other types in the future.

Lefkofsky’s wife Liz joins him in consistently donating to cancer research causes through their Lefkofsky Family Foundation, including money donated to New York’s Weill Cornell Medicine for breast cancer research in the amount of $250k.

Lefkofsky writes in his blog about how artificial intelligence is moving research forward, and of primary importance must be in healthcare. He explains how there is so many unused intel within data of molecular studies and documentation. Mentioned earlier,
he continually reiterates the significance of a personalized method of treatment; that there is a unique molecular map of each human being alive. Finding out the treasure to this map, so to speak, will give us the exact targets to attack in the fight against cancer by one thousand fold! This dictates personalized drugs, therapies, regimen and sequence.

“Accelerated Disruption: Understanding the True Speed of Innovation” (Easton Studio Press, 2007) is authored by the entrepreneur, shedding light on how so many businesses must understand and gain control of latest technological advances. Those that do will accomplish phenomenal feats; those who don’t or can’t will dissolve.

The 43-year-old seems to be just getting started in his latest undertaking of Tempus work, and will probably remain focused on healthcare research of causes and cures, if there truly is a cure, of cancer. This might be assured by his proven track record devoted to spending his lifetime, energy and unstoppable enthusiasm in uncovering, delving into, and figuring out the puzzles that seem to make up the many versions of cancer that plague so many people today.

What Eric Lefkofsky may offer the world, perhaps most importantly, is the gift of hope. Over one million people will be diagnosed with cancer in 2017, worldwide. Today, 4 out of 10 cancer patients will survive the symptoms of their disease. Annually to date, medical costs alone totals $37 billion. But perhaps the most motivating statistic is this: anyone, living anywhere, no matter how optimum their health is at risk.